Treating With HyperHEP B S/D

HyperHEP B S/D is an immunoglobulin that provides rapid immune coverage in potentially life-threatening situations.1 Vaccines can provide lifelong protection but take weeks to build efficacy, however, HyperHEP B S/D provides immediate protection that allows the vaccine the time needed to establish active immunity in high-risk situations.1-3

HyperHEP B S/D contains high titers of antibodies and provides passive immunity for postexposure prophylaxis (PEP), providing rapid immune protection.1,2 

Trusted Dependability

  • Established history—more than 45 years of consistent supply and product support
  • Mercury (thimerosal) and latex free
  • US Food and Drug Administration (FDA) labeling for capacity to remove pathogenic prions
  • Convenient prefilled syringes with BD UltraSafe® Needle Guards* to protect against needlestick injury
  • Tamper-evident packaging
  • 36-month shelf life
  • Only hepatitis B immune globulin product with a neonatal syringe

HyperHEP B S/D is indicated for PEP in the following situations1:

Acute Exposure to Blood Containing HBsAg

Hepatitis B virus (HBV) infection can develop after either parenteral exposure (eg, by accidental needlestick), direct mucous membrane contact (eg, accidental splash), or oral ingestion (eg, pipetting accident) involving hepatitis B surface antigen (HBsAg)-positive materials such as blood, plasma, or serum.

Perinatal Exposure of Infants Born to HBsAg-Positive Mothers

Infants born to HBsAg-positive mothers are at risk of being infected with HBV and becoming chronic carriers. This risk is especially high if the mother is hepatitis B e-antigen (HBeAg)-positive.

Sexual Exposure to an HBsAg-Positive Person

Sex partners of HBsAg-positive persons are at increased risk of acquiring HBV infection.

Household Exposure to Persons With Acute HBV Infection

Because infants have close contact with primary caregivers and have a higher risk of becoming HBV carriers after acute HBV infection, prophylaxis of an infant less than 12 months of age with HyperHEP B S/D and hepatitis B vaccine is indicated if the mother or primary caregiver has acute HBV infection.

Clinical Efficacy

Immediate Protection With HyperHEP B S/D1,4

The vaccine alone is not enough: immune globulins like HyperHEP B S/D, when used in combination with a vaccine, can prevent infection by hepatitis B. The administration of the recommended dose of this immune globulin generally results in a detectable level of circulating anti-HBs, which persists for approximately 2 months or longer.

Acute Exposure to Blood Containing HBsAg1

  • For inadvertent percutaneous exposure, a regimen of 2 doses of HyperHEP B S/D—1 given after exposure and 1 a month later—is about 75% effective in preventing hepatitis B in this setting

Perinatal Exposure of Infants Born to HBsAg-Positive Mothers1

  • For an infant with perinatal exposure to an HBsAg-positive and HBeAg-positive mother, a regimen combining 1 dose of HyperHEP B S/D at birth with the hepatitis B vaccine series started soon after birth is 85%–95% effective in preventing development of the HBV carrier state
  • Regimens involving either multiple doses of HyperHEP B S/D alone or the vaccine series alone have 70%–90% efficacy, while a single dose of HyperHEP B S/D alone has only 50% efficacy

Sexual Exposure to an HBsAg-Positive Person1

  • For sexual exposure to a person with acute hepatitis B, a single dose of HyperHEP B S/D is 75% effective if administered within 2 weeks of last sexual exposure

Safety Is a Priority1

Manufacturing Process

The HyperHEP B S/D manufacturing process is designed to decrease the infectivity of an experimental agent of transmissible spongiform encephalopathy (TSE), considered as a model for the Creutzfeldt-Jakob disease (CJD) and variant CJD agents.

HyperHEP B is made from human blood and may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Traceability and Transparency of Information

Grifols' manufacturing process has a comprehensive computer system called PediGri® that ensures full traceability from every donation.

  • Each plasma unit is coded and computer-traced from the start of the process until the units are transformed into a final product
  • Users can access the donation number and the viral screening conducted at the origin of the donation with the product lot number
    • Specific information is also available, including the total number of plasma units, the total volume of plasma, the certificate of analysis showing the plasma origin viral screening, and biochemical characteristics of the final product
  • Users can access the applicable product SPC/package insert for their country

For immediate, easy, and convenient access to all the information on the origin and quality of Grifols' plasma derivatives, visit

Dosing Recommendations for HyperHEP B S/D1

Coding Information

Download an informational guide about the Hypermunes portfolio. 

HyperHEP B® S/D (hepatitis B immune globulin [human]) is indicated for postexposure prophylaxis in the following situations: acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to an HBsAg-positive person, and household exposure to persons with acute HBV infection.

HyperHEP B S/D should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations. Epinephrine should be available.

In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, hepatitis B immune globulin (human) should be given only if the expected benefits outweigh the risks.

Local pain and tenderness at the injection site, urticaria, and angioedema may occur; anaphylactic reactions, although rare, have been reported following the injection of human immunoglobulin preparations. Administration of live virus vaccines (eg, MMR) should be deferred for approximately 3 months after hepatitis B immune globulin (human) administration.

HyperHEP B S/D is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products.

Please see full Prescribing Information for HyperHEP B S/D.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.


  1. HyperHEP B® S/D (hepatitis B immune globulin [human]) Prescribing Information. Grifols.
  2. Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond). 2007;57(8):552-556.
  3. Centers for Disease Control and Prevention. Principles of vaccination. In: Hamborsky J, Kroger A, Wolfe S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington, DC: Public Health Foundation; 2015:1-8. Accessed June 26, 2019.
  4. Centers for Disease Control and Prevention. Hepatitis B. In: Hamborsky J, Kroger A, Wolfe S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington, DC: Public Health Foundation; 2015:149-174. Accessed June 26, 2019.